Reliability of cytology to detect chlamydial infection in asymptomatic women

Vinette-Leduc, Danielle; Yazdi, Hossein M.; Jessamine, Peter; Peeling, Rosanna W.

doi:10.1002/(sici)1097-0339(199710)17:4<258::aid-dc4>3.0.co;2-8

Cited by 10 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are three liquidbased Pap tests (LPTs) approved by the United States Food and Drug Administration (FDA): PreservCyt ThinPrep (Cytyc, Boxborough, MA), SurePath (TriPath Care Technologies, Burlington, NC), and Cytotek MonoPrep (Monogen, Inc., Vernon Hills, IL). Liquid-based cytology has provided greater Pap testing accuracy, and the sample may serve as a specimen to test for infectious agents, such as human papillomavirus (2,11), Chlamydia trachomatis (5,14), and Neisseria gonorrhoeae (6,9). The APTIMA COMBO 2 assay, APTIMA CT assay for Chlamydia trachomatis, and AP-TIMA GC assay for Neisseria gonorrhoeae are transcriptionmediated amplification tests that utilize target capture specimen processing for the in vitro qualitative detection of rRNA from C. trachomatis and/or N. gonorrhoeae.…”

mentioning

confidence: 99%

Detection of Chlamydia trachomatis and Neisseria gonorrhoeae Infections in North American Women by Testing SurePath Liquid-Based Pap Specimens in APTIMA Assays

et al. 2007

View full text Add to dashboard Cite

The APTIMA COMBO 2 assay, which detects and amplifies rRNA from Chlamydia trachomatis and/or Neisseria gonorrhoeae, is approved for use on ThinPrep liquid-based Pap test specimens. The objective was to determine the clinical utility of the APTIMA assays (APTIMA COMBO 2 assay, APTIMA CT assay for Chlamydia trachomatis, and APTIMA GC assay for Neisseria gonorrhoeae) for screening women during their annual Pap exam, using SurePath liquid-based Pap test specimens. Two cervical samples were collected from 1,615 females attending six clinical sites in North America. A cervical broom sample was processed for cytology, with the residuum aliquoted into an APTIMA specimen transfer kit tube. The second cervical swab sample was put into APTIMA specimen transport medium, and both samples were tested with each APTIMA assay on a direct sampling system. Using a subject-infected status that utilized cervical-swab specimen results from two APTIMA assays, the prevalence was 7.9% for Chlamydia trachomatis and 2.5% for N. gonorrhoeae. Annual screening for cervical abnormalities using a Pap test has resulted in a substantial reduction in morbidity and mortality from cervical cancer (11). There are three liquidbased Pap tests (LPTs) approved by the United States Food and Drug Administration (FDA): PreservCyt ThinPrep (Cytyc, Boxborough, MA), SurePath (TriPath Care Technologies, Burlington, NC), and Cytotek MonoPrep (Monogen, Inc., Vernon Hills, IL). Liquid-based cytology has provided greater Pap testing accuracy, and the sample may serve as a specimen to test for infectious agents, such as human papillomavirus (2, 11), Chlamydia trachomatis (5, 14), and Neisseria gonorrhoeae (6, 9). The APTIMA COMBO 2 assay, APTIMA CT assay for Chlamydia trachomatis, and AP-TIMA GC assay for Neisseria gonorrhoeae are transcriptionmediated amplification tests that utilize target capture specimen processing for the in vitro qualitative detection of rRNA from C. trachomatis and/or N. gonorrhoeae. The assays are approved for use on cervical swab (CS) samples, vaginal swab samples, urethral swab samples, and first-catch urine samples. The APTIMA COMBO 2 assay is approved for use with ThinPrep LPT specimens. A limited number of studies have been published using both amplified and nonamplified tests for C. trachomatis or N. gonorrhoeae in liquid-based specimens and have concentrated on the use of ThinPrep samples (1, 5-10; D. Fuller, T. Davis, and J. Talbott, unpublished data). Our objective was to determine the clinical utility of the APTIMA assays (Gen-Probe Incorporated) for screening women for C. trachomatis and N. gonorrhoeae during their annual Pap examination by using SurePath LPT specimens. MATERIALS AND METHODSA total of 1,615 female subjects signed consent forms while being enrolled during 2004 at six clinical sites in North America: University of North Carolina (UNC), Chapel Hill, NC; University of Alabama (UAB), Birmingham, AL; St. Joseph's Healthcare (SJH), Hamilton, ON, Canada; University of OklahomaTulsa (UOT), Tulsa, OK; University of Illinoi...

show abstract

mentioning

confidence: 99%

Detection of Chlamydia trachomatis and Neisseria gonorrhoeae Infections in North American Women by Testing SurePath Liquid-Based Pap Specimens in APTIMA Assays

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This simple, rapid, readily accessible method is also known to provide clues in diagnosing STIs, with the associated inflammatory changes [28]. Several studies have been conducted to assess the utility of this method in CT diagnosis in the past [29][30][31][32][33][34]. Some studies have highlighted the association of cervical epithelial changes and cytological variations including increased histiocytes and transformed lymphocytes with CT infections, indicating Pap smears as screening tests [28,29].…”

Section: Cervical Cytologymentioning

confidence: 99%

“…However, these changes may not be unique to CT infections [30]. In addition, ample data on poor sensitivity of this methodology, provided by various research reports, has marked it as an unreliable method both in screening and diagnosis of CT infections [31][32][33][34].…”

Section: Cervical Cytologymentioning

confidence: 99%

Diagnosis of Chlamydia trachomatis genital infections in the era of genomic medicine

Shetty

Kouskouti

Schoen³

et al. 2021

Braz J Microbiol

View full text Add to dashboard Cite

Purpose Chlamydial genital infections constitute significant sexually transmitted infections worldwide. The often asymptomatic status of C. trachomatis (CT) infections leads to an increased burden on human reproductive health, especially in middle- and low-income settings. Early detection and management of these infections could play a decisive role in controlling this public health burden. The objective of this review is to provide an insight into the evolution of diagnostic methods for CT infections through the development of new molecular technologies, emphasizing on -omics’ technologies and their significance as diagnostic tools both for effective patient management and control of disease transmission. Methods Narrative review of the diagnostic methodologies of CT infections and the impact of the introduction of -omics’ technologies on their diagnosis by review of the literature. Results Various methodologies are discussed with respect to working principles, required specifications, advantages, and disadvantages. Implementing the most accurate methods in diagnosis is highlighted as the cornerstone in managing CT infections. Conclusion Diagnostics based on -omics’ technologies are considered to be the most pertinent modalities in CT testing when compared to other available methods. There is a need to modify these effective and accurate diagnostic tools in order to render them more available and feasible in all settings, especially aiming on turning them to rapid point-of-care tests for effective patient management and disease control.

show abstract